The 30th JFCR－ISCC
December 11-12, 2026
Tomizo Yoshida Memorial Auditorium
3-8-31, Ariake Koto-ku, Tokyo, Japan
December 11
12:00-12:30
Committee meeting
Opening Remark
12:50-13:00
Naoya Fujita (Cancer Chemotherapy Center, JFCR)
Opening remark
Session I: Metabolic regulation to improve immune micro-environment
13:00-13:40
Ping-Chi Ho (Ludwig Insitute for Cancer Research)
Can you remember, exhausted T cells?
13:40-14:10
Kenji Chamoto (Kyoto University Graduate School of Medicine)
Mitochondrial FAO prevents T cell exhaustion by reducing aldehyde
14:10-14:40
Shogo Kumagai (Cancer Precision Medicine Center, JFCR)
Revealing the metabolic basis of cancer immunotherapy resistance
14:40-14:50
Discussion
14:50-15:10
Coffee Break
Meet-the-Expert 1: From undruggable to druggable
15:10-16:00
Charles G. Drake (Johnson & Johnson Innovative Medicine)
JNJ-6143: A novel AR-Targeted RIP-TAC for prostate cancer
16:00-16:10
Discussion
Poster Flash talk
16:10-17:20
Ayane Nakamura (Cancer Chemotherapy Center, JFCR)
RK-582, a tankyrase inhibitor, potentiates immune checkpoint blockade by remodeling the tumor immune microenvironment
Maryuki Ueda (Chugai Pharmaceutical Co., Ltd.)
AUBE00: A novel cyclic peptide pan-KRAS inhibitor targeting KRAS-activated cancers including KRAS-mutant cancers and wild-type colorectal cancer
Hiroyoshi Tanaka (Okayama University)
Novel 3D cell culture model of the fibrotic barrier in pancreatic cancer for mechanistic analyses and target identification
Hiroaki Tanaka (Astellas Pharma Inc.)
TBD
Ryuji Tamaki (Eisai Co., Ltd)
Cell-free DNA based inference of the activities of 370 + transcription factors mirrors their activities in tumors
Naoki Shijubou (Sapporo Medical University School of Medicine)
The ΔNp63–IL-1α axis in immune responsiveness and immune escape in lung squamous cell carcinoma
Yoshihide Kakimoto (MSD K.K.)
CARDINAL: A Phase 1 study of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for patients with previously treated CML
Shandan (Kanazawa University Cancer Research Institute)
Endothelial expression of FJX1 drives angiogenic activity of lung ECs and promotes breast cancer cell stemness at the metastatic site
TBD (Cancer Chemotherapy Center, JFCR)
TBD
Poster viewing and networking
17:20-18:50
December 12
Session II: Revolution for pancreatic cancer therapy
9:00-9:40
TBD
9:40-10:20
Adam Crystal (Tango Therapeutics)
TBD
10:20-10:50
Atsushi Enomoto (Nagoya University Graduate School of Medicine)
Targeting cancer-associated fibroblast heterogeneity to enhance drug delivery
10:50-11:00
Discussion
11:00-11:20
Coffee Break
Meet-the-Expert 2
11:20-12:00
Ryan Corcoran (Mass General Brigham Cancer Institute, MGH)
No longer undruggable: advances in targeting RAS-driven cancers
12:00-12:10
Discussion
Luncheon seminar
12:20-13:10
TBD
13:10-13:20
Break
Session III: Rising star session
13:20-13:50
Naofumi Uesaka (Institute of Science Tokyo)
Translating neural activity into oncogenic signaling in glioma
13:50-14:30
Israel Canadas (Fox Chase Cancer Center)
When tumors act like viruses: Exploiting viral mimicry for cancer therapy
14:30-14:40
Discussion
14:40-15:00
Coffee Break
Session IV: Other target and drugs
15:00-15:30
Akiko Kimura (Takeda Pharmaceutical Company Limited)
Development of PD-1/IL-2α-bispecific fusion protein
15:30-16:00
Shinya Ishii (Chugai Pharmaceutical Co., Ltd.)
Beyond Binding: Expanding Therapeutic Possibilities through Antibody Engineering
16:00-16:30
Toshiyoshi Fujiwara (Kagawa Rosai Hospital)
Multidisciplinary oncolytic virotherapy for esophageal cancer patients unfit for standard treatments
16:30-16:40
Discussion
Closing remark
16:40-16:50
Ryan Corcoran (Mass General Brigham Cancer Institute, MGH)
Closing remark